Industry
Biotechnology
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Loading...
Open
3.30
Mkt cap
2.8M
Volume
111K
High
3.70
P/E Ratio
-0.20
52-wk high
18.81
Low
3.07
Div yield
N/A
52-wk low
2.40
Portfolio Pulse from Avi Kapoor
July 29, 2024 | 5:19 pm
Portfolio Pulse from Benzinga Newsdesk
July 05, 2024 | 3:02 pm
Portfolio Pulse from Benzinga Newsdesk
July 05, 2024 | 3:01 pm
Portfolio Pulse from Benzinga Newsdesk
July 05, 2024 | 2:59 pm
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 11:36 am
Portfolio Pulse from Benzinga Newsdesk
June 18, 2024 | 11:34 am
Portfolio Pulse from Avi Kapoor
June 12, 2024 | 11:07 am
Portfolio Pulse from Avi Kapoor
June 11, 2024 | 11:27 am
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 8:49 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.